Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Control Groups × Genitourinary × Clear all

Phase

Status

Unknown 1 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3 Genitourinary 1 Gastrointestinal 1

Conditions

Testicular Neoplasms 1 Motor Activity 1

Interventions

Docetaxel 59 pembrolizumab 35 Prednisone 34 Nivolumab 33 enzalutamide 29 Gemcitabine 29 Sunitinib 28 Cyclophosphamide 26 Leuprolide 22 Everolimus 21 Sorafenib 20 Radiotherapy 20 Magnetic Resonance Spectroscopy 20 Abiraterone Acetate 18 bicalutamide 17 Cisplatin 17 avelumab 15 Interleukin-2 15 Radiosurgery 14 Goserelin 14 Carboplatin 14 fludarabine 13 atezolizumab 13 Radiotherapy, Intensity-Modulated 13 Bevacizumab 13 abiraterone 12 Doxorubicin 12 durvalumab 11 cabazitaxel 11 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02577172 2017-01-26

TAST

Oslo University Hospital

Phase NA Terminated

Motor Activity, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡